JP2016088926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016088926A5 JP2016088926A5 JP2015043590A JP2015043590A JP2016088926A5 JP 2016088926 A5 JP2016088926 A5 JP 2016088926A5 JP 2015043590 A JP2015043590 A JP 2015043590A JP 2015043590 A JP2015043590 A JP 2015043590A JP 2016088926 A5 JP2016088926 A5 JP 2016088926A5
- Authority
- JP
- Japan
- Prior art keywords
- ikaros
- inflammatory
- substance
- test substance
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150016712 IKZF1 gene Proteins 0.000 claims 16
- 239000002260 anti-inflammatory agent Substances 0.000 claims 13
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 claims 12
- 206010061218 Inflammation Diseases 0.000 claims 11
- 230000004054 inflammatory process Effects 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 230000014509 gene expression Effects 0.000 claims 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 4
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 210000000981 epithelium Anatomy 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 3
- 108010013958 Ikaros Transcription Factor Proteins 0.000 claims 2
- 102000017182 Ikaros Transcription Factor Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 claims 1
- 125000002575 PGE2 group Chemical group 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002986 dinoprostone Drugs 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014223295 | 2014-10-31 | ||
| JP2014223295 | 2014-10-31 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016088926A JP2016088926A (ja) | 2016-05-23 |
| JP2016088926A5 true JP2016088926A5 (enExample) | 2018-03-22 |
| JP6653120B2 JP6653120B2 (ja) | 2020-02-26 |
Family
ID=56017549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015043590A Active JP6653120B2 (ja) | 2014-10-31 | 2015-03-05 | Ｉｋａｒｏｓ阻害に基づく抗炎症薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6653120B2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2968628T3 (es) * | 2019-09-03 | 2024-05-13 | Square Power Ltd | Rebamipida para uso en prevención y tratamiento de la enfermedad de Crohn |
| CN111961702A (zh) * | 2020-07-22 | 2020-11-20 | 上海珈蓓生物科技有限公司 | 植提物抗皮肤感染性炎症反应的细胞学评价方法及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2123406A1 (en) * | 1992-09-14 | 1994-03-31 | Katia Georgopoulos | Ikaros: a t cell pathway regulatory gene |
| JPH1029942A (ja) * | 1996-04-02 | 1998-02-03 | Yoichi Ichikawa | 慢性関節リウマチ治療剤 |
| WO2010019210A2 (en) * | 2008-08-11 | 2010-02-18 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
| ES2872967T3 (es) * | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| WO2015127351A1 (en) * | 2014-02-24 | 2015-08-27 | Celgene Corporation | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders |
-
2015
- 2015-03-05 JP JP2015043590A patent/JP6653120B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | The senescence-associated secretory phenotype and its physiological and pathological implications | |
| Locati et al. | Macrophage activation and polarization as an adaptive component of innate immunity | |
| Barutta et al. | Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment | |
| King et al. | Biomarkers of multiorgan injury in a preclinical model of exertional heat stroke | |
| WO2015176066A3 (en) | Lpa-associated protein and rna expression | |
| Zheng et al. | JNK inhibitor SP600125 protects against lipopolysaccharide-induced acute lung injury via upregulation of claudin-4 | |
| JP2019518063A5 (enExample) | ||
| JP2019201663A5 (ja) | ファルネシルトランスフェラーゼ阻害剤に応答する患者を同定するためのアッセイ | |
| Shen et al. | Ethyl pyruvate pretreatment attenuates concanavalin a-induced autoimmune hepatitis in mice | |
| Li et al. | Calcitonin gene-related peptide is a promising marker in ulcerative colitis | |
| JP2016528914A5 (enExample) | ||
| JP2016088926A5 (enExample) | ||
| JP2015530094A5 (enExample) | ||
| JP2016531843A5 (enExample) | ||
| Liu et al. | HMGB1 translocation and expression is caused by warm ischemia reperfusion injury, but not by partial hepatectomy in rats | |
| RU2018104707A (ru) | ИСПОЛЬЗОВАНИЕ МОЛЕКУЛЯРНЫХ МАРКЕРОВ IL-3, IL-33 и IL12ρ40 ДЛЯ ХАРАКТЕРИСТИКИ СТЕПЕНИ ТЯЖЕСТИ РЕСПИРАТОРНЫХ ИНФЕКЦИЙ, ВЫЗВАННЫХ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫМ ВИРУСОМ ЧЕЛОВЕКА И МЕТАПНЕВМОВИРУСОМ ЧЕЛОВЕКА | |
| Xin et al. | Circulating cell-free DNA indicates M1/M2 responses during septic peritonitis | |
| JP2015520744A5 (enExample) | ||
| Mahmutovic-Persson et al. | Capacity of capsazepinoids to relax human small airways and inhibit TLR3-induced TSLP and IFNβ production in diseased bronchial epithelial cells | |
| JP2016511822A5 (enExample) | ||
| WO2014139884A3 (en) | Molecular targets and inhibitors of said targets, useful in the treatment of fibrosis | |
| JP2015194481A5 (enExample) | ||
| JP2014208601A5 (enExample) | ||
| RU2017139718A (ru) | Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост для таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток | |
| Hong et al. | Lymphatic System in the Liver |